论文部分内容阅读
对于神经母细胞瘤复发或顽症而其它治疗手段又无效的患者,131 I-MIBG(131 I-间碘苄胍)曾作为一种缓解性治疗手段。因其治疗效果颇佳,就产生了将它与其它治疗手段联用,或作为首期治疗(up-fronttreatm ent)的想法。目前的研究结果表明,131 I-MIBG的辐射效应与化疗的协同作用将会成为最佳的临床治疗手段,可避免采用那些更具毒性和侵袭性的治疗方法。
131I-MIBG (131I-melinumab) was used as a palliative treatment for patients with recurrent or persistent neuroblastoma and other treatments that are ineffective. Because of its well-curative effect, there is an idea of using it in combination with other therapies or as an up-front treatment. The current findings suggest that the synergistic effect of 131 I-MIBG radiotherapy and chemotherapy will be the best clinical treatment to avoid, using more toxic and aggressive treatments.